CNTA240719P2500
- 0.05
- 0.000.00%
Centessa Pharmaceuticals Newsroom
Centessa Pharmaceuticals Price Target Announced at $14.00/Share by Oppenheimer
Centessa Pharmaceuticals Price Target Announced at $14.00/Share by
Centessa Pharmaceuticals Initiated at Outperform by Oppenheimer
Centessa Pharmaceuticals Initiated at Outperform by
Oppenheimer Initiates Centessa Pharmaceuticals(CNTA.US) With Buy Rating, Announces Target Price $14
Oppenheimer analyst Francois Brisebois initiates coverage on $Centessa Pharmaceuticals(CNTA.US)$ with a buy rating, and sets the target price at $14.According to TipRanks data, the analyst has a
Express News | Centessa Pharmaceuticals PLC : Oppenheimer Initiates Coverage With Outperform Rating; Target Price $14
Oppenheimer Initiates Centessa Pharmaceuticals at Outperform Rating With $14 Price Target
Centessa Pharmaceuticals (CNTA) has an average buy rating and a price target range of $11 to $20, according to analysts polled by Capital IQ.
Centessa Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
Centessa Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
Centessa Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/21/2024 11.56% Morgan Stanley $8 → $11 Maintains Equal-Weight 04/01/2024 52.13% BMO Capital $15 → $15 M
Express News | Centessa Pharmaceuticals, Inc : Morgan Stanley Raises Target Price to $11.00 From $8.00
Morgan Stanley Maintains Centessa Pharmaceuticals(CNTA.US) With Hold Rating, Raises Target Price to $11
Morgan Stanley analyst Jeffrey Hung maintains $Centessa Pharmaceuticals(CNTA.US)$ with a hold rating, and adjusts the target price from $8 to $11.According to TipRanks data, the analyst has a success
Centessa Pharmaceuticals Plc's (NASDAQ:CNTA) Institutional Investors Lost 12% Over the Past Week but Have Profited From Longer-term Gains
Key Insights Significantly high institutional ownership implies Centessa Pharmaceuticals' stock price is sensitive to their trading actions A total of 8 investors have a majority stake in the compan
Centessa Pharma Hires CFO From Fusion After AstraZeneca Takeover
By Dean Seal Centessa Pharmaceuticals has hired the former chief financial officer of Fusion Pharmaceuticals after the latter company was acquired by AstraZeneca. The clinical-stage pharmaceutical c
Centessa Pharma Taps John Crowley, as CFO, Effective June 10
Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that John Crowle
Press Release: Centessa Pharmaceuticals Strengthens Executive Leadership With Appointment of John Crowley CPA, as Chief Financial Officer and Gregory Weinhoff MD MBA, as Chief Business Officer
Centessa Pharmaceuticals Strengthens Executive Leadership with Appointment of John Crowley CPA, as Chief Financial Officer and Gregory Weinhoff MD MBA, as Chief Business Officer BOSTON and LONDON, Ju
Nxera Pharma to Receive $4.6 Million Milestone Payments From Centessa Pharmaceuticals
Nxera Pharma (TYO:4565) anticiaptes obtaining $4.6 million in milestone payments from Centessa Pharmaceuticals under a license agreement for Nxera's technology, according to its Thursday filing. This
Check out the disclosed information for [Tomorrow's Good and Bad Materials]! (Announced on 5/30)
[Good Material] ――――――――――■Sanyo Homes [Tokyo Stock Exchange S] formulated a medium-term management plan. We aim for operating profit of 2.4 billion yen for the fiscal year ending 27/3 (results for the fiscal year ending 24/3 are 950 million yen). ■Petroleum Resources Development [TSE P] Participated in the “Freeport LNG Project” in Texas, USA. ■Kudo Construction [TSE S] will additionally acquire shares of Nikken Kikaku, which is an affiliated company applying the equity method, and make it a consolidated subsidiary. ■TOENEC
Nxera Pharma to Receive $4.6 Million in Milestone Payments From Centessa Pharmaceuticals
Tokyo, Japan and Cambridge, UK, 30 May 2024 – Nxera Pharma ("the Company" or "Nxera"; TSE: 4565) today announced that it expects to receive $4.6 million in milestone payments from Centessa Pharmaceuticals pursuant to a
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
Analysts Have Conflicting Sentiments on These Healthcare Companies: AlloVir (ALVR), Guardant Health (GH) and Centessa Pharmaceuticals (CNTA)
Centessa Pharmaceuticals | 10-Q: Quarterly report
Centessa Pharmaceuticals 1Q Loss/Shr 38c >CNTA
Centessa Pharmaceuticals 1Q Loss/Shr 38c >CNTA